23ME01473 is under clinical development by 23andMe Holding and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how 23ME01473’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
23ME01473 overview
23ME01473 is under development for the treatment of metastatic solid tumors, sarcoma, squamous lung cancer, head and neck squamous cell carcinoma, colorectal cancer and triple negative cancer. It acts by targeting ULBP6/2/5. It is administered through intravenous route.
23AndMe Holding overview
23andMe Holding provides genetic test solutions to study ancestry, genealogy, and inherited traits that markets its data into categorized and searchable form to researchers. The company is headquartered in South San Francisco, California, the US.
For a complete picture of 23ME01473’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.